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Abstract 
 
 
The Disease Control Priorities Project (DCPP) is a three-year effort to help inform 
disease control priorities in developing countries at a regional level using economic 
evaluation of specified interventions, an assessment of the size of the disease burden and 
consideration of how best to scale up interventions within a health system context. As 
part of the project a set of standardized regional unit costs have been estimated for a 
range of health care resource inputs.  This Working Paper presents these data on the unit 
costs of health care inputs for the six low and middle-income World Bank regions.  The 
aim is to provide DCPP chapter authors with a set of unit costs and ratios of relative costs 
for different regions in order that the same estimates and ratios are used in the analysis of 
a ‘DCPP base case’.  The objectives of this Working Paper are to: introduce and justify 
the approach taken to unit pricing for regions; provide preliminary results; illustrate how 
such information might be used; and discuss the pros and cons of the approach we have 
taken.  In addition the paper explores some of the methodological issues around 
estimating costs and highlights where further research is required. 
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1  INTRODUCTION 
 
The Disease Control Priorities Project (DCPP) is a three-year effort to help inform 
disease control priorities in developing countries at a regional level using economic 
evaluation of specified interventions, an assessment of the size of the disease burden and 
consideration of how best to scale up interventions within a health system context. 
Maintaining comparability of costs across diverse regions and studies will be a key part 
in facilitating comparison across chapters and across the diverse range of diseases and 
interventions.  
 
As part of the project, a set of standardized regional unit costs have been estimated for a 
range of health care resource inputs.  The aim is to provide DCPP chapter authors with a 
set of unit costs and ratios of relative costs for different regions in order that the same 
estimates are used in the analysis of a ‘DCPP base case’.  It is also the intention that 
providing these data will facilitate examination and re-estimation of costs within chapters 
and by readers of the book, Disease Control Priorities in Developing Countries. 
 
The objectives of this Working Paper are to introduce and justify the approach taken to 
unit pricing for regions; provide preliminary results; illustrate how such information 
might be used; and discuss the pros and cons of the approach we have taken. 
1.1 Context 
 
Economic evaluation, and particularly cost-effectiveness analysis (CEA), has gained 
credence in recent years as a policy tool relevant for decision-making at all levels.  At the 
national level, for example, the British National Institute of Clinical Excellence publishes 
guidance about appropriate clinical care that is based partly on cost-effectiveness 
(National Institute for Clinical Excellence, 2001).  CEA has also been used as part of the 
process for decision-making at the district level.  For example, Finlay et al (1995) 
described a four year project based in two districts in Tanzania that set out to “test the 
hypothesis that burden of disease and cost-effectiveness analysis should provide the basis 
 
   
for health services planning in low income countries” (Finlay et al., 1995 p1083).  At a 
broader international level, cost-effectiveness analysis became a more visible tool for 
policy making following publication of the 1993 World Development Report (World 
Bank, 1993) and its companion volume on Disease Control Priorities (Jamison et al., 
1993).   
 
The increasing demand, coupled with limited research resources and paucity of current 
evidence, for undertaking the economic evaluation of health interventions is creating 
pressure to use data from one setting in another (Walker and Fox-Rushby, 2000a).  This 
pressure is felt at international, national and sub-national levels. However this has led to 
two major concerns. First, how should costs, effects and cost-effectiveness ratios be most 
appropriately transferred across settings? and second, to what extent are existing ratios 
comparable given the diverse methods employed in evaluations to date?  
 
The pressure to transfer data on cost-effectiveness from one setting to another is not new 
and currently happens in a variety of ways.  For example, economic evaluations 
undertaken alongside randomized clinical trials are often based on costs measured at one 
site and extrapolated to all other sites in the trial, often with no consideration of the 
external validity of the trial or its impact on actual costs in practice (Glick et al., 2001). 
Costs measured outside trials are often ‘top-down costings’, reducing the ability to assess 
variation.  Results of economic evaluations are often not subject to sensitivity analysis or 
considered in the light of: budget or resource constraints; scale of production; or basic 
contextual data such as time period and nature of provider units. Results are rarely 
presented in a way that allows costs, quantities, utilization, or effects to be disaggregated 
(Walker and Fox-Rushby, 2000b)   
 
In practice, the presentation of cost-effectiveness results and the transfer of cost-
effectiveness ratios from one setting to another imply that cost-effectiveness ratios are not 
subject to uncertainty, that results do not vary according to known or unknown factors, 
and that decision-making is not affected by the constraints of different contexts. Direct 
transfer of costs and cost-effectiveness results assumes that costs are the same across 
 
   
settings and, without dis-aggregate presentation of the results, cost-effectiveness ratios 
cannot be re-constructed for adaptation to different settings; thus,  generalisability 
remains untested and untestable. 
 
There are increasing concerns about the ability of global or regional analyses of cost-
effectiveness to account adequately for local circumstances (Kumaranayake and Walker, 
(in press); Fox-Rushby and Parker, 1995) and a number of publications have highlighted 
problems faced in transferring results between settings (Mason, 1997; Drummond et al., 
1992; Spath et al., 1999; Bryan and Brown, 1998).  However, policy makers are often 
hindered in their decision making both by the paucity of available data and because of 
uncertainty on how results can or should be transferred between settings1.   
 
The paucity of data and lack of knowledge about whether and why cost-
effectiveness/benefit ratios vary is a cause for concern.  As Box 1 outlines, there are a 
range of potential causes of variation in cost-effectiveness ratios for the same 
intervention. Even without accounting for the impact of different budgets, all could 
potentially affect decisions about which kinds of interventions to fund.  The potential bias 
and inefficiencies involved in transferring data without resolving our understanding of 
the causes of variation could not only introduce inefficient interventions and halt the 
provision of efficient interventions, but also harm a nation’s health and welfare.  
Alternatively, variation within and between settings may not exist or may make little 
difference.  It is therefore vital to assess how serious a problem this is and whether it 
leads to any systematic misallocation of resources. 
 
                                                 
1 We are not implying that good decisions are not made with available evidence, just that there is little to 
guide decision-makers’ understanding of the size and likelihood of alternative outcomes of their decisions 
with respect to actual average and incremental costs (or costs at differing levels of production) or effects of 
alternative interventions. 
 
   
 
BOX 1: Factors that could account for differences in cost-effectiveness ratios for the 
same intervention 
 
¾ demography / epidemiology of disease 
¾ availability of health care resources 
¾ variations in clinical practice 
¾ incentives to health care professionals and institutions 
¾ absolute and relative costs 
¾ exact specification of the intervention 
¾ scale of the intervention 
¾ combinations of the intervention with other services 
¾ methodological differences, including: 
 
 definition of cost 
 methods of identification, measurement and valuation of costs and benefits 
 discount rate 
 data availability 
 identification of the margin 
 choice of the comparison 
 
 
The second major area of concern in the field of economic evaluation concerns the 
quality and comparability of current evidence.  Growing recognition of the need for 
improved quality and for some ‘standardization’ in methods has led to a plethora of 
published guidelines and movement towards some consensus of what should be 
incorporated within any evaluation (Hjelmgren et al., 2001).  Of particular note are the 
guidelines developed by an expert group, The US Panel on Cost-Effectiveness in Health 
and Medicine. They recommended a series of standardized methods and positions to 
adopt for a ‘reference case analysis’ for any published paper.  The details and specific 
recommendations are set out by Gold et al. (1996). 
 
1.2 DCPP standardized unit costs 
 
The second edition of DCPP is intended to update the first edition and to go beyond it in 
a number of important ways. In particular, a key aim is to ensure greater uniformity in the 
approach towards the applied cost-effectiveness analyses. Cost-effectiveness analysis as 
undertaken for DCPP is intended to be consistent with the methods of Gold et al. (1996), 
 
   
modified to assess large changes from the status quo as described in Jamison (2002).  As 
part of this endeavor, the Project is providing DCPP chapter authors with a set of 
standardized unit costs for the six low and middle income World Bank regions (East Asia 
& Pacific, Europe and Central Asia, Latin America & Caribbean, Middle East & North 
Africa, South Asia and Sub Saharan Africa), to enable comparison across chapters.    
 
A range of international datasets on costs or prices of inputs to health services already 
exist (see for example Adam et al., 2003; Johns et al., 2003; Hutton, 2001; 
Kumaranayake et al., 2001; Schwartländer et al., 2001). Probably the most ambitious 
dataset and set of estimations is that assembled by the Global Program on Evidence for 
Health Policy of the WHO (Adam et al., 2003; Johns et al., 2003). This work, known as 
WHO-CHOICE, started in 1998 with the development of standard tools and methods and 
represents the first systematic attempt to estimate unit costs at both the patient and 
program level for health interventions in all countries and regions of the world. This 
makes it possible to generate unit costs that are not only consistent across interventions 
within one country, but also allows for comparison across countries with similar 
determinants such as background epidemiology and socioeconomic factors, as well as 
estimating the cost of scaling up interventions to different coverage levels by varying 
capacity utilization.    One key finding from this work is that unit costs of many health 
inputs vary substantially both between and within countries. This implies that basing 
cost-effectiveness studies for a region or country on the results of a study of a single 
facility, or even a small group of facilities, is likely to be misleading (Adam et al., 2003).   
 
MEDTAP International, in conjunction with a group of pharmaceutical companies, also 
embarked on a project in 1998 to collate a comparable set of unit cost data for health care 
resources in eight European and North American health systems and six disease areas 
(Hutton, 2001)2.  The aim of this data set is to produce unit cost data for use in economic 
evaluations,with the objective of obtaining consistency within each country’s list of 
resource items, given that economic evaluations are conducted on a country-specific 
                                                 
2 The countries are Canada, France, Germany, Italy, Spain, Sweden, UK and US. Diseases are Cancer, 
Cardiovascular disease, AIDS/HIV, Mental Illness, Alzheimer’s disease and Stroke. 
 
   
basis. Thus the intention is to produce data which are justifiable and acceptable to the 
audiences for economic evaluation in each country. Given that all the estimates are drawn 
from a small set of highly developed countries, the data are probably of less relevance to 
low and middle income settings. However, the process of drawing together the data has 
highlighted the areas where further work is required. In particular the developers argue 
that there is a need for better data on costs of diagnostic tests and this finding resonates 
with other efforts to establish the costs of laboratory services in developing countries 
(Liverpool School of Tropical Medicine, 2002). 
 
In addition to cross-country datasets, there also exist numerous national datasets of unit 
costs within high income countries. The most comprehensive cost data come from the 
United States where efficiency concerns within the publicly financed Medicare program 
for the elderly led to new methods for measuring costs on a diagnosis basis (Glick et al., 
2001). In the United States, sources of cost data include: hospital charges adjusted using 
cost to charge ratios; data from internal hospital costing systems; diagnosis related group 
payments for hospitalizations (Department of Health and Human Services, 1991a); and 
resource-based relative value units for physician services (Department of Health and 
Human Services, 1991b; Hsiao et al. 1992). Data readily available in Europe include: the 
UK national reference costs dataset produced by the UK Department of Health 
(Department of Health, 2002); a comprehensive dataset on health and social care costs in 
the UK by Netten and Curtis (2002); data produced by the Healthcare Financial 
Management Association (2001) on UK health service costs; official data produced for 
German hospitals which give the relative scale of the costs of procedures (BPflV, 1998); 
inpatient hospitalization costs in France (Hopitaux de Paris, 1996); and diagnostic related 
group tariffs from the Italian National Health Service (Ministerio della Sanita 1997). 
 
Datasets of costs in developing countries are harder to find and there is a heavier reliance 
on specific costing studies for particular diseases or hospitals. Barnum and Kutzin (1993) 
categorize hospital studies as ‘step down’ or cost finding analyses, and accounting 
statistics studies.  The first group examines ex-post hospital expenditures in terms of 
different areas of hospital production. The second group relies on generally available 
 
   
hospital information reported to central or regional government.  The former group is the 
most useful for costing hospital services as data routinely produced by hospitals are often 
too general and non-specific (Lewis et al., 1996). Cost finding studies include those by 
Mills et al. (1989), Raymond et al. (1986), Russell et al. (1988), Valli et al. (1991) and 
Hongoro and McPake (2003). In each case the authors adopt a step-down methodology 
which allocates direct and indirect expenditures across cost centers.  While such studies 
are able to distinguish where resources are distributed, they give no account of  how 
resources are actually applied in practice (Lewis, 1996).  The expenditures on producing 
the service are clear, but the actual cost of producing that service is less so. There are 
studies which document the actual costs of providing health services in developing 
country settings (see for example Fox-Rushby and Foord, 1993; Villar et al., 2002 and 
Aikins et al., 1998).  However these are not usually nationally representative, are often 
for a limited number of interventions, and employ different costing methodologies 
(Walker and Fox-Rushby, 2000a).  Nevertheless, taken together, these studies represent 
the best data currently available for developing countries and, outside of disease specific 
costing studies, there have been very few attempts at improving this methodology in a 
systematic way. 
 
1.3 Current approaches to estimating unit costs 
 
Given the lack of data, a key question for DCPP is how to transfer existing unit price 
estimates to those countries where there are little or no data. The various methods 
employed in the literature can be broadly divided into econometric approaches where 
costs are estimated from regression models, and standardization approaches where 
estimates are taken from the literature for one or more countries and are extrapolated to 
the other countries using a variety of methods.   
 
There is a long history of econometric estimation of hospital costs (see for example, 
Feldstein, 1967, Lave and Lave 1970, Grannemann et al., 1986; Wagstaff and Barnum, 
1992; Bitran-Dicowsky and Dunlop, 1993; Li and Rosenman, 2001). These multi-variate 
models attempt to explain how costs per unit of activity vary in relation to a variety of 
 
   
variables such as hospital size, service mix, input prices and average length of stay. 
However  relatively few studies have attempted to explain differences in unit costs across  
different countries. The work by WHO-CHOICE represents the first systematic attempt 
to develop a model to estimate country-specific costs using macro-level indicators such 
as GDP per capita and other determinants such as capacity utilization and types of costs 
included (Adam et al., 2003 and Johns et al., 2003).  Glick et al. (2003) also attempted to 
develop a method of estimating unit costs, for hospital diagnoses for four countries in 
Europe, and found that average length of stay in the US was a good predictor of unit 
costs. 
 
A variety of methods for standardizing or transferring costs across different countries or 
regions are also encountered in the literature (see for example Schwartländer et al., 2001, 
Kumaranayake et al. 2001, Schulman et al. 1998).  However, detailed information on 
methods and assumptions behind transferring unit cost estimates to regions or countries is 
often not available. One of the exceptions is the work by Schulman et al. (1998). Here, 
the authors developed a standardized costing methodology in seven countries and applied 
it to the costing of treatments for subarachnoid haemorrhage. Where unit costs estimates 
were not available the analysts developed an index table based on a “market basket 
approach” reflecting the relative costs of a basket of resources for six services for which 
unit cost data were available for all countries. The Commission for Macroeconomics and 
Health (Kumaranayake et al. 2001) employed an apparently similar approach, but used a 
regional index based on purchasing power parities to transfer between the unit costs of 
priority health interventions.  
2 DCPP METHODS 
 
2.1  Frames of reference  
 
The aim is to produce price data suitable for chapter authors to use in estimating the cost-
effectiveness (or cost-benefit) of a wide range of health care interventions in six low and 
middle income World Bank regions. Annex 1 lists the countries included within each 
region.  As chapter authors were guided to use an ingredients approach to calculating 
 
   
costs (Disease Control Priorities Project, 2003) the aim of this exercise was to provide a 
set of standardized unit costs, by region.  Multiplying these costs by intervention specific 
quantities of resource inputs (defined by chapter authors) would then form the basis for 
estimating the change in total costs of moving from one (set of) health  intervention(s) to 
another.  Making costs explicit in this way fosters a clear separation of costs and 
quantities in economic evaluations.  Both costs and quantities can be subject to sensitivity 
analysis within the economic analyses and the extent to which quantities respond to either 
differences in the relative price of inputs or different scales of production can be 
considered, to help  promote understanding about variation in cost-effectiveness ratios.  It 
also allows analysts and policy makers to validate the assumptions used and assess the 
extent to which the estimates can be applied to their settings.    
 
The costs provided are intended to reflect delivery through a public health system and, as 
far as possible, the opportunity cost of health resources in each World Bank region.  
However, as the speed of the exercise also required that the data be collated from publicly 
accessible sources, the guiding principles were to use the best available data, to adjust as 
far as possible where deviations were obvious, and to retain transparency in all data 
manipulations.   
  
2.2 Classification of health care inputs 
 
We first identified those inputs important either in explaining the total cost or variations 
in cost.  WHO CHOICE divides costs into “patient costs”, those incurred at the point of 
delivery of health interventions, such as cost of a lab test, outpatient visit, surgical 
operation; and “program costs”, which are costs incurred at a level other than the point of 
delivery of the intervention, and where overhead or general administrative activities such 
as planning, supervision, training, media and outreach are involved. Using these two 
broad categories, we provide information for patient costs on the unit cost per in-patient 
day, ambulatory visit at hospital outpatient departments or health centers, key diagnostic 
and surgical procedures; and for program costs on annual salary, transport operation, 
building and equipment costs. As can be noted from this classification, the ingredients 
 
   
approach is implemented differently for patient and program costs. We use unit cost per 
output, such as outpatient visit, for patient costs and per factor input such as personnel, 
supplies and capital for program costs.  
 
Certain types of costs did not need to be provided.  For example we did not provide 
information on drug prices as authors could readily access comprehensive price lists. The 
International Drug Price Indicator Guide published by Management Sciences for Health 
is recommended as the principal source of prices (see http://erc.msh.org). 
 
2.3 Sources of data 
 
Much of the unit price data and methods presented here is based on data collected and 
collated by the WHO-CHOICE project (see http://www.who.int/evidence/cea  for more 
detail).  As noted earlier, WHO-CHOICE attempted to assess the overall costs and effects 
of a wide variety of health interventions by region. This has involved the development of 
models to predict unit costs in different countries based on key macroeconomic indicators 
such as GDP per capita (Warner, 2002; Rodrik, 1999; Liu and Hsiao,1995; Newhouse, 
1992 and Peden and Freeland, 1998).  Because of concerns about the appropriateness of 
transferability of unit costs from single studies, or even groups of studies, we have used 
the results of the models developed by WHO-CHOICE to generate unit price data for 
individual countries. The results are aggregated to the World Bank regions using regional 
population weights. Full details of the model specification employed for the analyses are 
provided in Annex 2.   
 
Where we did not employ WHO-CHOICE models to estimate costs in different regions, 
e.g. for laboratory and procedure costs, we relied on a review of published and  
unpublished studies to obtain unit price data for each region.  Given the paucity of data 
for some categories, we had to use a number of sources with differing methods of data 
collection and interpretation, and undertook standardization where necessary.  Table 1 
summarises types and sources of cost data.   
 
 
   
Table 1. Types of costs and sources 
Type Sources 
Traded goods  
Equipment WHO Product Information Sheets (2000) 
Durbin Price Catelogue  2003 
Gerry Mission Supplies 
  
Non-traded goods  
Salaries WHO-CHOICE 
Buildings Gardiner & Theobald (2002) 
http://www.gardiner.com/Projects/Projects.htm. (Extracted 
05/05/03) 
 
Davis Langdon & Seah International. Cost data - major cities 
in Asia. http://www.davislangdon-
asia.com/dlasiacostdata.html . 2003. (Extracted 20/07/03). 
Levett & Bailey. China - construction costs data. 
http://www.lnb.com.hk/costs-data/china/cost-
constructioncosts-data-yr2000-1.html. 2000. (Extracted 
20/07/03) 
Davis Langdon & Seah International. Cost data. 
http://www.davislangdon.com/dlafrica/html/dlflcostdata2.html 
. 200. (Extracted 20/07/03). 
 
  
Mixed goods and services  
Hospital inpatient day WHO-CHOICE 
Hospital outpatient visit WHO-CHOICE 
Health center visit WHO-CHOICE 
Laboratory and hospital procedures Essential Laboratory Services Project (2001) 
Goodman et al. (2000) 
Schwartländer et al. (2001) 
Barnum (1983) 
Floyd et al. (1997) 
Marseille (1999) 
Shepard (1993) 
 
Fuel costs World Bank (2003) 
Metschies (1999) 
 
Vehicle operating costs World Bank (2003) 
Metschies (1999) 
 South African Automobile Association (2003)  
 
  
 
2.4 Unit of account 
 
International comparisons of costs and effects require that unit costs reflect the economic 
cost of goods and allow for inter-country comparison of interventions during the same 
 
   
time period (Hutton and Baltussen, 2002). For this reason, the world price level was 
chosen as the price level and all results are presented in 2001 US Dollars.   
 
To transfer costs across time, we used World Bank gross domestic product implicit price 
deflators (World Bank 2003).  This measures the change in the price level of GDP 
relative to real output and has an advantage over consumer price indices as it is not based 
on a fixed basket of goods and services. Changes in consumption patterns or the 
introduction of new goods and services (for example the rate at which a country is 
investing in technology, which is relevant for the health sector) are therefore better 
reflected.  
 
2.5 Dealing with traded and non-traded goods 
 
As shown in Table 1 health inputs can be distinguished by whether they are traded or 
non-traded.  Traded goods are commodities that are available on the international market, 
and in theory, all countries can purchase them at an international market price. The 
international price can therefore be considered to reflect the opportunity cost of 
purchasing traded goods to a country, adjusted to include insurance and freight (c.i.f) for 
imported goods.  In each case we attempted to find the lowest price available, with 
optimum quality, to represent the socially efficient price.  We excluded import duties and 
subsidies from the price since these are transfer payments from one part of the economy 
to another and does not involve the use of resources.   Prices were derived from WHO 
publications and non-governmental organisations operating at an international level and 
excluded costs of shipment and taxes.  We asked authors to assume a baseline 15% mark-
up for shipping and handling charges and an additional 10% to account for distribution 
costs (Sawert, 1996).  However, given that distribution costs vary widely and are 
dependent on a complex combination of geography, infrastructure, administrative barriers 
and the structure of the shipping industry (Limao and Veneables, 2001), we also asked 
authors to explore this variation in their sensitivity analyses.   
 
In contrast to traded goods, the price of non traded and mixed goods like labor are likely 
to vary across regions.  Therefore it is necessary to estimate costs on a regional basis.  In 
 
   
many instances the distinction between traded and non traded is not so straightforward 
and most inputs are made up of a traded and non-traded component. Fuel is one example 
where there exists an international price, but in practice there are regional costs of 
distribution which influence the untaxed retail pump price.  The costs of medical 
procedures such as laboratory tests also comprise traded (equipment, drugs and supplies) 
and non-traded (labor, buildings) components. For these kinds of mixed inputs we have 
also estimated regional costs.  
 
2.6 Standardizing costs across regions 
 
For the costs of inputs with a non-tradable component which were not derived from 
WHO-CHOICE data, it was necessary to transfer and standardize unit price estimates 
across regions.  Our aim was to convert costs obtained in one region into the likely costs 
in other regions.  We assumed that the country specific estimate or average of estimates 
de facto represented the region in which the country resided.  To assign costs for regions 
where data were missing, we adopted a similar methodology to Schulman et al. (1998) 
and developed an index table that reflected the relative costs of hospital services for pairs 
of regions in the study.  These indices were derived from population weighted regional 
averages of hospital inpatient unit price estimates (see section 2.7 below).  For example, 
in Sub-Saharan Africa the estimated cost of a hospital inpatient day in a primary level 
facility was $6.17.  In Latin America and the Caribbean, the cost was $26.57. To create 
the SSA-LAC index, we divided the SSA cost per bed day by the LAC cost per bed day 
giving an index value of 0.32. This pair-wise comparison was performed 36 times to 
develop a complete set of pair-wise comparisons for all six regions (see Table 2).   
 
Where only one data point existed, the point estimate was divided into traded and non-
traded components and the appropriate regional price index (see Table 2) was applied to 
the non-traded components to arrive at relative costs for the other regions. Where data 
existed for more than one data point in a region, the average was calculated to arrive at 
the point estimate and the highest and lowest estimates used to provide the range. Where 
data existed for data points in more than one region, the most ‘appropriate’ regional 
 
   
estimate (or average of estimates) was used before applying regional weights to the non-
traded component.  For example if estimates for Sub-Saharan Africa and South Asia 
existed, the estimate(s) for South Asia was considered as appropriate to use for East Asia 
and Pacific.  
 
Country specific data were converted to US 2001 dollars and the appropriate regional 
index was applied to the non-traded components of costs to reflect relative differences in 
input prices. Where price data were transferred across countries and time, we made the 
time adjustment first followed by the currency conversion.  
 
Table 2.  Relative hospital cost indices for World Bank regions 
 
WB region EAP ECA LAC MNA SA SSA 
       
EAP 1.00 0.67 0.65 0.86 1.55 2.03 
ECA 1.50 1.00 0.97 1.29 2.32 3.03 
LAC 1.54 1.03 1.00 1.32 2.39 3.12 
MNA 1.16 0.78 0.76 1.00 1.81 2.36 
SA 0.64 0.43 0.42 0.55 1.00 1.31 
SSA 0.49 0.33 0.32 0.42 0.77 1.00 
       
 
Cost indices derived from a weighted average of  hospital inpatient costs. These costs were estimated using 
a regression model for public hospitals with 80% occupancy rate.  Estimate includes hotel costs of hospital 
stay (capital, salaries,  building, equipment and food) (see Adam et al. 2003). 
 
 
2.7 Approaches and assumptions behind pricing of each health care input or 
service 
 
This section describes the specific methods used to estimate each type of unit price for 
each health care input or service.   
 
Hospital costs per bed day and outpatient visits 
 
Unit cost per bed day was estimated using an Ordinary Least Squares regression model 
developed by WHO-CHOICE  and published by Adam et al. (2003) (See Annex 2.1). 
 
   
The WHO dataset used to develop this model included estimates from the published 
literature and specially commissioned country studies. Unit cost data were drawn from 49 
countries, with a total of 2173 country-years of observations from the period 1973-2000, 
96% of which were after 1990. The model predicts unit costs with different specifications 
by setting the values of the explanatory variables as required. It also allows for 
differences in the level of capacity utilization, which is an important source of variation 
in unit costs. It controls for cross-country price level differences using unit costs adjusted 
for purchasing power parity, and for differences in quantity and complexity of resource 
use using per capita GDP. For chapter authors, we predicted unit costs with the “hotel” 
component only, i.e., including overhead, salaries, food and capital and excluding 
ancillary and drug costs. They are estimated by country and hospital level (see definition 
of level in Box 2) for public hospitals working at 80% capacity. Country level GDP per 
capita were collected and results estimated for all countries of the World Bank regions.  
Results were averaged using country population weights (see Box 3 for a worked 
example). High and low estimates are also provided, reflecting the upper and lower 
ranges obtained for each region.    
 
Box 2. Hospital level definitions adopted by WHO-CHOICE 
 
Primary-level hospital: Has few specialities, mainly internal medicine, obstetrics-gynecology, 
paediatrics, general surgery or just general practitioners; limited laboratory services are available 
for general but not for specialized pathological analysis; bed size ranging from 30-200 beds; often 
referred to as district hospitals or first level referral.  
 
Secondary-level hospital: Highly differentiated by function with five to ten clinical specialities; 
bed size ranging from 200-800 beds; often referred to as provincial hospital.  
 
Tertiary-level hospital: Highly specialized staff and technical equipment, e.g.cardiology, ICU 
and specialized imaging units; clinical services are highly differentiated by function; might have 
teaching activities; bed size ranging from 300-1,500 beds; often referred to as central, regional or 
tertiary level hospital.  
 
 
 
Hospital costs per outpatient visit are also based on a WHO-CHOICE model (see Annex 
2.2), using the same dataset. In this case the model predicts the ratio of the cost per 
 
   
outpatient visit to the cost per hospital bed day.  The results of the model together with 
estimates of cost per bed-day from the model presented above are used to calculate the 
cost per outpatient visit by level of hospital, ownership and country . 
.Health center visits 
 
The third source of information using the WHO-CHOICE datasets is cost per visit at 
health centers. Several steps and models are involved. First, a model was developed to 
estimate the unit cost per health center visit at different levels of capacity utilization, 
defined as the average number of visits per health worker per day. The results show that 
as capacity increases the unit cost per visit decreases reflecting the presence of economies 
of scale. Again this model employed a mix of data from commissioned costing studies 
and the literature with a total of 481 observations from the period 1980-2001.   Second, 
region-specific data on the maximum number of visits per health worker per day, when 
health workers are working at 80% capacity and optimum quality; the average visits per 
person per year; and the yearly number of working days in health centers were used to 
construct the catchment areas around a primary health facility. These data were then 
entered in a Geographical Information Systems (GIS) model to determine the capacity 
utilization of each health center in the region. This was done by assuming that health 
centers are placed not more than 1 hour travel distance from the catchment population. 
The model assumes that as coverage expands, and health facilities are placed in more 
remote areas, capacity utlization declines since the 1-hour-travel-distance assumption in 
more remote areas will lead to a reduced catchment population. Therefore facilities in 
remote areas are expected to operate at less than full capacity, which leads to higher unit 
costs. Using this information and the parameters estimated from the first model, unit cost 
per visit was calculated at different coverage levels, namely 50%, 80% and 90%. The 
estimated unit cost includes capital costs but excludes the costs of laboratory procedures 
and other ancillary services.  Country-specific macro-economic data were used to 
generate country level results, which were averaged to give regional estimates using 
country population weights. High and low estimates are provided, reflecting the upper 
and lower country level results obtained for each region.   Details of the parameters 
 
   
estimated from the unit cost model can be found in Annex 2.3 (see Adam et al., 
forthcoming). 
 
Labor 
 
The estimation of labor costs in each region originate from a WHO-CHOICE regression 
model.  Regional expert teams provided the data on local costs for different categories of 
labor for reference countries in their regions. WHO-CHOICE also obtained 
supplementary information from other sources on country-specific costs of labor, most 
notably the International Labor Organization database on occupational salaries. The 
model predicts regional salaries for five grades of staff using a dataset of 752 
observations for 72 countries (see Box 3 for definitions of staff level). The unit price 
refers to the gross wage received by the employee and includes paid vacation and 
regularly paid guarantees or allowances (such as social security). It does not, however 
include costs such as overtime, bonuses, etc. The model controls for cross country price 
level differences using per capita GDP, population density and WHO region. The final 
model predicted salaries in US dollars for the 14 WHO regions. The results were then 
mapped to the six World Bank regions using country population weights.  High and low 
estimates are provided reflecting the upper and lower results obtained.  Full details of the 
model specification and coefficients employed are provided in Annex 2.4 (see Johns et 
al., forthcoming)  
 
Box 3 WHO-CHOICE definitions of staff levels  
The job categories were divided into five educational levels, corresponding to UNESCO's educational 
classifications.  
 
Level 1: requires lower secondary education or second stage of basic education (e.g. Cleaner, Porter, 
Transport Driver) 
 
Level 2:  requires (upper) secondary education (e.g. Health worker, Data Entry Clerk, receptionist) 
 
Level 3: requires post-secondary non-tertiary education, or first stage of tertiary education (e.g. Registered 
Nurse, Health Educator Trainer) 
 
Level 4: requires second stage of tertiary education (leading to an advanced research qualification) (e.g. 
Medical Officer, Public Health Specialist, Nursing Manager) 
 
 
   
Level 5: same as level 4 but requires additional substantial work experience or specialist training (e.g. 
Medical Specialist, Program Director) 
 
(UNESCO, 1999) 
 
Laboratory and hospital procedures 
 
Many disease treatments require a selection of common laboratory, diagnostic and 
surgical procedures. We undertook a review to obtain cost data for ten laboratory and 
diagnostic procedures for each of the regional groupings. These procedures were: malaria 
microscopy, malaria dipstick test, blood transfusion, TB microscopy test, stool 
microscopy test, blood test, HIV voluntary counselling and testing, operating theatre 
time, X-ray test, generic laboratory cost per patient. The choice of procedures was largely 
pragmatic and chosen on the basis that they were important to many of the diseases 
covered by DCPP and data were easily available. Sources of data included a mix of 
published and unpublished data (Goodman et al., 2000; Floyd et al., 1997; Liverpool 
School of Tropical Medicine, 2002, Schwartländer, 2001; Barnum, 1983; Shepard, 1993, 
Hongoro, personal communication 2003).  
 
Where more than one observation was found,  the mean of the estimates available for the 
appropriate region was used as the best estimate and a high-low range provided.  
However in several instances only a single estimate could be obtained and in these 
instances simply a point estimate is provided. Where an estimate could not be found for a 
particular region, costs were standardized as outlined in section 2.7. Items were broken 
down by their estimated tradable and non-tradable components and regional price 
adjustments were undertaken for the non-tradable component using regional cost indices.  
A worked example is provided in Box 4. To transfer costs across time we used World 
Bank GDP price deflators.   
  
 
   
 
Box 4  Standardizing costs across regions for hospital and laboratory procedures 
  
In estimating relative costs for different regions, a number of approaches were adopted depending 
on the nature of the original price data.  
 
Where only one data point existed 
 
In this situation, we divided the point estimate into traded and non-traded components and 
applied regional hospital price indices shown in Table 2 to the non-traded components to arrive at 
relative costs for the other regions. 
 
Worked example:  A stool microscopy test 
 
Estimate from Malawi, SSA =  $0.67  
 
Step 1  Split estimate into tradable/non-tradable components 
 
  Tradable  $0.58 (87%) 
  Non-tradable $0.09 (13%) 
 
Step 2 Multiply non-tradable component by SSA regional weight from Table 9  
  i.e.  $0.09 * 2.03 for EAP 
   $0.09 * 3.03 for ECA and so on: 
 
Step 3  Add tradable and non-tradable components together to arrive at regional estimate 
       
     World Bank region 
    EAP ECA LAC MNA SA SSA  
  Tradable $0.58 $0.58 $0.58 $0.58 $0.58 $0.58 
 Non-tradable $0.18 $0.27 $0.28 $0.21 $0.12 $0.09 
  
 Total  $0.76 $0.85 $0.86 $0.79 $0.70 $0.67  
 
This approach can be used by authors for their own costs. If the breakdown between traded and 
non-traded components is unknown, analysts can apply the appropriate regional weight to the 
entire estimate. 
 
Where data existed for more than one data point in a region 
 
For all available estimates regional costs were calculated as above. The average taken as the  
point estimate and the highest and lowest estimates were used to provide the range. 
 
Where data existed for data points in more than one region 
 
For the remaining regions the most appropriate available regional estimate was used before 
applying regional weights to the non-traded component.  For example if estimates from Sub 
Saharan Africa and South Asia existed, the estimate from South Asia was used for East Asia and 
Pacific.  
 
 
   
 
 
Transport 
 
Although fuel is an internationally traded good, to reflect regional differences in the price 
of distribution we estimated the regional price of the most widely sold grade using data 
collected by GTZ (see Metschies, 1999) and reproduced by the World Bank (2003). 
However these sources give the pump price of fuel including all taxes and subsidies.  To 
estimate the regional untaxed pump price we adopted the methodology suggested by 
WHO-CHOICE. We divided all countries into four regions based on GTZ’s classification 
(subsidized prices, low tax, middle tax and high tax). We then subtracted the minimum 
tax rate for these classifications (since an average tax rate results in some negative 
numbers). For countries subsidising gasoline prices we inputted the international untaxed 
pump price.  Although this method does not completely eliminate taxes it brings the 
pump price closer to the untaxed price. 
 
Equipment 
 
International prices for capital equipment and medical supplies were derived from price 
indices in WHO publications and catalogues of prices from non-governmental 
organisations. In general the lowest international listed price with optimum quality was 
selected which assumes that health facilities are able to purchase items in bulk (Johns et 
al., 2003).  
 
Buildings 
 
Although in the short term there are not many alternative uses of health care facilities and 
thus the opportunity cost of these building is close to zero, in the longer term there are 
options such as use in other public activities. Therefore, it is important to provide 
regional estimates of building costs for some interventions.  Several international 
construction cost surveys were reviewed and the replacement cost per square metre (i.e. 
 
   
the cost of constructing a similar building today) was calculated for an office and a basic 
building in an urban location.  The equivalent annual cost was estimated by annualising 
the total cost over an expected life of 20 years and at a discount rate of 3%.   
 
 3 RESULTS 
 
Tables 3-12 provide a breakdown of unit costs by health care resource category for each 
World Bank region in US dollars.  In general, costs tend to be higher in Europe and 
Central Asia, and Latin America and the Caribbean, for all health care inputs.  For 
example the price of a hospital bed-day in a primary level health facility ranges between 
a low of $6.17 in Sub- Saharan Africa and a high of $26.57 in Latin America and the 
Caribbean.  An annual salary for a Level 1 job (e.g. health auxiliary) ranges between 
$1,287 in South Asia to $5,576 in the Middle East and North Africa.   There is 
considerable variation in those laboratory and diagnostic procedures which have a high 
non-tradable component. For example, the estimated cost of voluntary counselling and 
testing per patient ranges from $9.33 in sub-Saharan Africa to $25.16 in Latin America 
and the Caribbean. Similarly, a minute of operating theatre time ranges from $1.68 in Sub 
Saharan Africa to $4.66 in the Americas. There is less variation across regions in 
procedures with a low non-tradable component such as malaria microscopy tests ($0.50– 
$0.80) and stool microscopy test ($0.67 – $0.86).   
 
 
   
 
Table 3. Cost per inpatient hospital bed day (USD, 2001) 
 
World Bank region Hospital level Best Low High 
 
       
East Asia and Pacific Primary $8.47 $3.06 $48.75 
  Secondary $11.04 $4.00 $63.59 
  Tertiary $15.09 $5.46 $86.86 
          
Europe and Central Asia Primary $15.08 $2.78 $34.27 
  Secondary $19.67 $3.63 $44.70 
  Tertiary $26.87 $4.96 $61.06 
          
Latin America and Caribbean Primary $26.57 $6.43 $48.61 
  Secondary $34.66 $8.39 $63.42 
  Tertiary $47.35 $11.46 $86.62 
          
Middle East and North Africa Primary $20.71 $2.78 $59.38 
  Secondary $27.02 $3.63 $77.47 
  Tertiary $36.91 $4.96 $105.81 
          
South Asia Primary $6.51 $2.64 $14.52 
  Secondary $8.50 $3.45 $18.94 
  Tertiary $11.61 $2.64 $25.87 
          
Sub-Saharan Africa Primary $6.17 $1.92 $41.79 
  Secondary $8.05 $2.51 $54.52 
  Tertiary $10.99 $3.42 $74.47 
     
 
 
Table 4. Cost per outpatient hospital visit (USD, 2001) 
 
World Bank region Hospital level Best Low High 
 
       
East Asia and Pacific Primary $2.20 $0.80 $12.67 
  Secondary $3.09 $1.12 $17.81 
  Tertiary $4.68 $1.69 $26.93 
          
Europe and Central Asia Primary $4.42 $0.82 $10.05 
  Secondary $6.30 $1.16 $14.31 
  Tertiary $9.32 $1.72 $21.17 
          
Latin America and Caribbean Primary $7.44 $1.80 $13.61 
  Secondary $10.40 $2.52 $19.02 
  Tertiary $15.39 $3.73 $28.15 
          
Middle East and North Africa Primary $5.54 $0.74 $15.88 
  Secondary $7.77 $1.04 $22.27 
  Tertiary $11.53 $1.55 $33.07 
          
South Asia Primary $1.67 $0.68 $3.73 
 
   
World Bank region Hospital level Best Low High 
 
  Secondary $2.35 $0.95 $5.24 
  Tertiary $3.52 $0.80 $7.85 
          
Sub-Saharan Africa Primary $1.48 $0.46 $10.03 
  Secondary $2.13 $0.66 $14.45 
  Tertiary $3.13 $0.98 $21.22 
     
 
Table 5. Cost per health center visit (USD, 2001)  
 
World Bank region Population 
coverage level 
Best Low High 
         
East Asia and Pacific 90% $1.30 $0.76 $4.10 
  80% $1.01 $0.59 $3.18 
  50% $0.94 $0.55 $2.97 
          
Europe and Central Asia 90% $1.91 $0.56 $4.10 
  80% $1.48 $0.43 $3.17 
  50% $1.39 $0.40 $2.97 
          
Latin America and Caribbean 90% $3.35 $1.78 $6.57 
  80% $2.59 $1.38 $5.09 
  50% $2.43 $1.29 $4.76 
          
Middle East and North Africa 90% $3.10 $0.95 $10.63 
  80% $2.40 $0.74 $8.23 
  50% $2.24 $0.69 $7.70 
          
South Asia 90% $1.43 $0.74 $2.34 
  80% $1.19 $0.58 $1.81 
  50% $1.03 $0.54 $1.69 
          
Sub-Saharan Africa 90% $1.42 $0.66 $4.39 
  80% $1.10 $0.51 $3.40 
  50% $1.03 $0.47 $3.18 
 
Table 6. Annual Salaries (USD, 2001) 
 
 
World Bank region  Level 
 
Best Low High 
     
East Asia and Pacific Level 1 Jobs $1,443 $943 $2,062 
  Level 2 Jobs $1,850 $1,245 $2,586 
  Level 3 Jobs $2,668 $1,782 $3,787 
  Level 4 Jobs $4,491 $2,986 $6,369 
 Level 5 Jobs $7,093 $4,398 $10,385 
 
   
World Bank region  Level Best Low High 
 
       
Europe and Central Asia Level 1 Jobs $1,746 $1,224 $2,292 
  Level 2 Jobs $2,237 $1,616 $2,901 
  Level 3 Jobs $3,226 $2,301 $4,167 
  Level 4 Jobs $5,432 $3,904 $7,091 
 Level 5 Jobs $8,579 $5,806 $12,046 
       
Latin America and Caribbean Level 1 Jobs $3,431 $1,552 $4,045 
  Level 2 Jobs $4,397 $2,034 $5,057 
  Level 3 Jobs $6,341 $2,927 $7,407 
  Level 4 Jobs $10,677 $4,853 $12,407 
 Level 5 Jobs $16,861 $7,246 $20,874 
       
Middle East and North Africa Level 1 Jobs $5,576 $1,517 $12,337 
  Level 2 Jobs $7,145 $1,953 $15,638 
  Level 3 Jobs $10,306 $2,817 $23,034 
  Level 4 Jobs $17,351 $4,714 $38,286 
 Level 5 Jobs $27,403 $7,138 $64,401 
       
South Asia Level 1 Jobs $1,287 $925 $4,356 
  Level 2 Jobs $1,649 $1,221 $5,585 
  Level 3 Jobs $2,378 $1,747 $8,178 
  Level 4 Jobs $4,004 $2,929 $13,590 
 Level 5 Jobs $6,323 $4,313 $22,501 
       
Sub-Saharan Africa Level 1 Jobs $1,779 $1,320 $4,281 
  Level 2 Jobs $2,280 $1,706 $5,489 
  Level 3 Jobs $3,289 $2,486 $8,038 
  Level 4 Jobs $5,537 $4,143 $13,356 
 Level 5 Jobs $8,744 $6,165 $22,113 
     
 
 
Table 7. Daily salary rates (USD, 2001) 
 
World Bank region Level 
 
Best Low High 
     
East Asia and Pacific Level 1 Jobs $6.87 $4.49 $9.82 
  Level 2 Jobs $8.81 $5.93 $12.31 
  Level 3 Jobs $12.70 $8.48 $18.03 
  Level 4 Jobs $21.39 $14.22 $30.33 
 Level 5 Jobs $33.78 $20.94 $49.45 
       
Europe and Central Asia Level 1 Jobs $8.31 $5.83 $10.92 
  Level 2 Jobs $10.65 $7.69 $13.81 
  Level 3 Jobs $15.36 $10.96 $19.84 
  Level 4 Jobs $25.87 $18.59 $33.77 
 Level 5 Jobs $40.85 $27.65 $57.36 
       
Latin America and Caribbean Level 1 Jobs $16.34 $7.39 $19.26 
 
   
 
World Bank region Level 
 
Best Low High
  Level 2 Jobs $20.94 $9.69 $24.08 
  Level 3 Jobs $30.20 $13.94 $35.27 
  Level 4 Jobs $50.84 $23.11 $59.08 
 Level 5 Jobs $80.29 $34.51 $99.40 
       
Middle East and North Africa Level 1 Jobs $26.55 $7.22 $58.75 
  Level 2 Jobs $34.03 $9.30 $74.47 
  Level 3 Jobs $49.07 $13.42 $109.69 
  Level 4 Jobs $82.63 $22.45 $182.31 
 Level 5 Jobs $130.49 $33.99 $306.67 
       
South Asia Level 1 Jobs $6.13 $4.41 $20.74 
  Level 2 Jobs $7.85 $5.81 $26.60 
  Level 3 Jobs $11.32 $8.32 $38.95 
  Level 4 Jobs $19.07 $13.95 $64.71 
 Level 5 Jobs $30.11 $20.54 $107.15 
       
Sub-Saharan Africa Level 1 Jobs $8.47 $6.28 $20.39 
  Level 2 Jobs $10.86 $8.12 $26.14 
  Level 3 Jobs $15.66 $11.84 $38.27 
  Level 4 Jobs $26.37 $19.73 $63.60 
 Level 5 Jobs $41.64 $29.36 $105.30 
 
Notes 
• Based on an estimated working year of 42 weeks p.a. 5 days p.w. 
 
 
 
 
   
 
 Table 8. Costs of selected laboratory tests and hospital procedures (US dollars, 2001)  
 
        Region
EAP
 
ECA
 
LAC
 
MNA
 
SA SSA Sources
 
Malaria Microscopy test
 
         
      
       
       
 
       
Best $0.62 $0.75 $0.80 $0.67 $0.52 $0.50 Essential Laboratory Services Project (2001) 
Low $0.42 $0.51 $0.54 $0.46 $0.36 $0.34 Goodman et al. (2000) 
High $0.80
 
$0.96
 
$1.02
 
$0.86
 
$0.67
 
$0.64
 
 
 
 
Malaria Dipstick test 
Best $1.96      
        
       
 
       
$2.09 $2.11 $2.00 $1.86 $1.82 Goodman et al. (2000) 
Low $1.58 $1.69 $1.70 $1.61 $1.50 $1.46 Yeung personal communication
High $2.30
 
$2.46
 
$2.48
 
$2.35
 
$2.19
 
$2.14
 
 
 
Cost per unit of safe blood transfused 
        
        
       
       
 
       
Best $18.93 $21.37 $21.58 $19.73 $17.18 $16.43 Essential Laboratory Services Project (2001)
Low $13.71 $15.48 $15.63 $14.29 $12.44 $11.91 Schwartländer et al. (2001)  
High $24.14
 
$27.25
 
$27.52
 
$25.17
 
$21.91
 
$20.96
 
 
 
 
TB Microscopy test
 
         
      
       
       
        
Best $1.72 $2.25 $2.29 $1.89 $1.34 $1.18 Essential Laboratory Services Project (2001) 
 Low $1.19 $1.56 $1.59 $1.31 $0.93 $0.82 Barnum (1983)  
High $2.18
 
$2.85
 
$2.91
 
$2.40
 
$1.70
 
$1.50
 
Floyd et al.. (1997) 
  
Stool microscopy test        
       
        
Point estimate only 
 
$0.76
 
$0.85
 
$0.86
 
$0.79
 
$0.70
 
$0.67
 
Essential Laboratory Services Project  (2001)
 
Haemoglobin test          
        
   
        
 
   
 
 
 
 
  Region     
EAP ECA LAC MNA SA SSA Sources 
       
        Point estimate only $2.57 $3.40 $3.47 $2.84 $1.97 $1.72 Essential Laboratory Services Project (2001)
        
        
HIV: Voluntary counselling and testing, per 
person       
      
      
      
 
        
 
Best $17.00 $24.51 $25.16 $19.48 $11.62 $9.33 Schwartländer et al. (2001) 
Low $9.69 $13.96 $14.33 $11.09 $6.62 $5.32 Marseille (1999)
 
 
High 
 
$35.84
 
$51.67
 
$53.02
 
$41.05
 
$24.49
 
$19.67
 
Operating theatre time, cost per minute 
 
       
       
        
Point estimate only
 
$3.12
 
$4.53
 
$4.66
 
$3.59
 
$2.11
 
$1.68
 
Shepard (1993)
 
X ray test, per test        
       
       
       
Point estimate only $9.64
 
$13.90
 
$14.27
 
$11.04
 
$6.59
 
$5.29
 
Barnum (1983)
  
Generic laboratory cost per patient  
Point estimate only $8.90 $11.52 $11.74 $9.76 $7.02 $6.22 Personal communication with Dr Charles
Hongoro, LSHTM. 
 
 
Notes on all lab and procedure costs   
• Includes staff, equipment, supplies and overheads  
• Split into traded and non-traded components. Regional price adjustments made to non-traded components 
• District hospital setting 
 
Notes on blood transfusion costs       
• Includes all the costs associated with screening the donor for anaemia, hepatitis B, syphilis and HIV, bleeding the donor, determining the blood group of the 
donor and the recipient and checking the donor recipient compatibility of the blood. 
       
Notes on Haemoglobin test 
• Using HCN reference method
   
Table 9. Selected equipment costs (USD, 2001) 
 
Item Unit cost Estimated 
useful life 
years (a) 
Source 
        
Vehicles       
4 Wheel Drive 4000 cc (Toyota Landcruiser 
hardtop) 
$24,238 9 Gerry Mission Supplies 
(personal communication) 
Motorcycle 97 cc (on/off road) $1,491 7 WHO (2000) 
        
Major Equipment       
Portable X ray Unit $7,150 10 Durbin PLC (2002) 
Reconditioned  Mobile X ray unit $3,972 5 Durbin PLC (2002) 
Refrigerator $278 11 Durbin PLC (2002) 
Refrigerator, tropical, transportable $1,653 11 Durbin PLC (2002) 
        
Instruments and other equipment       
Microscope $542 10 Durbin PLC (2002) 
Sphygmomanometers (hand held with adult cuff) $14 8 Durbin PLC (2002) 
Stethoscope (economy model) $6 8 Durbin PLC (2002) 
Thermometers $1 8 Durbin PLC (2002) 
Weighing scales (infant and toddlers) $68 8 Durbin PLC (2002) 
Weighing scales (new born infants) $26 8 Durbin PLC (2002) 
Vaccine carrier (1.7 litres) $33 6 Durbin PLC (2002) 
Vaccine carrier (0.6 lites) $97 6 Durbin PLC (2002) 
       
 
Notes 
 
• Life expectancies taken from Goodman (2000), Halbwachs (2000) and WHO-CHOICE. Assumes 
equipment was bought in good condition and well maintained. 
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 Table 10.  Fuel, cost per litre (USD, 2001) 
 
World Bank region Regional 
estimate 
International 
price 
   
East Asia and Pacific  $        0.10  $0.24 
Europe and Central Asia  $        0.24  $0.24 
Latin America and Caribbean  $        0.30  $0.24 
Middle East and North Africa  $        0.20  $0.24 
South Asia  $        0.28  $0.24 
Sub-Saharan Africa 
 
 $        0.26  $0.24 
 
 
Table 11. Building cost per square metre (USD, 2001) 
 
World Bank region Best estimate 
 
 Office* Basic*
  
East Asia and Pacific $51.20 $18.37
Europe and Central Asia $52.83 $22.07
Latin America and Caribbean $24.05 $10.25
Middle East and North Africa $52.96 $28.41
South Asia $22.76 $12.44
Sub-Saharan Africa $22.95 $13.19
    
  
Notes 
• Office: building cost for a typical building in an urban location. Includes suspended ceilings, air-
conditioning, lighting and power. Excludes partitioning and all equipment and facilities.  
 
• Basic: building cost for a basic unit in an urban location with services and heating to the office 
space (approx 5% of area) 
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4 DISCUSSION 
 
This paper presents the unit costs of selected health care inputs for the six low and middle 
income World Bank regions. The main objective of this work was to provide DCPP 
chapter authors with a consistent set of costs to incorporate into their cost-effectiveness 
analyses.  However, others interested in comparisons across countries and regions may 
also find uses for these data. Those involved in multi-country costing studies may also 
find useful our description of the methods to estimate data for regions where we could 
find no data.  More generally, policy makers need information on the regional cost of 
inputs to feed into global estimates of the scale of resources required to tackle priority 
diseases such as malaria, TB, HIV/AIDS (Kumaranayake, 2001; Schwartländer et al., 
2001, Opuni et al., 2002), and regional or national estimates of costs provide support to 
decision making on how to allocate resources across diseases and countries.       
 
As Hutton and Baltussen (2002) also found, it became clear during the course of this 
work that the question of how to transfer cost data between countries and regions has 
received relatively little attention in the literature.  It is hoped that the data and methods 
presented here can be used in a number of ways depending on the perspective of the user. 
For those conducting their own cost-effectiveness analyses on a regional basis, the input 
prices can be used directly to facilitate comparisons within the DCPP chapters.  The 
prices can also be used as an approximation for the cost of inputs in particular countries. 
(for example the country price of an input in Brazil can be assumed to be the same as the 
regional price for Latin America and the Caribbean).  The way in which the data are used 
within analyses themselves will depend on the extent to which information on resource 
use quantities are available.   Box 7 gives some illustrative examples for two different 
scenarios: i) where there is information on quantities for different health care inputs and 
ii) where there is information only on total costs for health inputs.  
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Box 7: How might the data be used? 
 
Chapter authors are expected to estimate the quantities of resources needed for each intervention 
and where relevant attach the standardized regional cost to obtain the total cost of an input in 
another region. 
 
Where data on quantities are available 
 
An intervention to deliver a vaccine to 10,000 children in a rural area is estimated to require 250 
person days and 60 days for supervision.  In this case the relevant unit costs provided here for the 
different regions can simply be multiplied by the quantity of resources as follows.  
 
Assuming level 1 salaries for the 250 person days and level 2 for supervision.  Total costs: 
 
In SSA: (250 x 8.47) + (60 x 10.86) =  $2769 
In LAC: (250 x 16.34) + (60 x 20.94) = $5341 
 
Analysts can then use the range of high and low costs and different quantities in the sensitivity 
analysis.   
 
To help adjust estimates of total cost when quantities are not available 
 
Often resource use quantities are not reported in the literature.  Instead only the proportion of 
costs attributable to an input might be known for a particular country or region. For example the 
total recurrent staff costs for health care workers to deliver the vaccine in SSA = $100,000 and 
labor costs are 35%.   
 
To obtain the equivalent cost in LAC use the ratio of LAC to SSA costs for level 1 staff to 
multiply the 35% of total costs in SSA to obtain new total cost of labor in LAC.   
 
Thus:  ratio of level 1 annual salaries between LAC and SSA is $3431: $1779 = 1.9 
 
new total costs of labor in LAC = 1.9 x $35,000 = Int. $66,500 
 
For a generic indicator of relative costs in the hospital sector, analysts can also use the regional 
hospital cost indices provided in Table 2 to transfer costs between regions.    
 
 
 
4.1 Critical consideration of methods 
 
Despite the fact that costs are often required for multinational studies, few analysts have 
explored the theory and practice of multi-country costing (Drummond and Pang, 2001). 
Comparisons with previous studies are also hampered by the fact that detailed 
descriptions of methods are often lacking. A key question that arises from this work is the 
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extent to which the regional estimates accurately reflect unit costs in the different World 
Bank regions. This leads to two sets of concerns. One concern relates to the validity of 
regional costs per se for certain health care inputs. For example, estimating regional 
prices for salaries is particularly problematic where monopsony power of local hospital 
employers leads to the true value of local wages being lower than is suggested by the data 
here. Equally, local purchasers of highly skilled labor (eg medical specialists or 
experienced program managers) may face a higher international rather than a regional 
price to reflect scarce labor which may mean the salary data presented here could be 
under-estimates of the true value.   
 
A second set of concerns relates to the validity of the methods used to estimate costs for 
regions.  Methods adopted here drew upon the results of two types of analyses, namely, 
econometric approaches (i.e. for the hospital, health center and salaries data) and 
standardization approaches where estimates are taken from the literature for one or more 
regions and are extrapolated to the remaining regions using relative price indices (i.e. for 
laboratory procedures, fuel and vehicle costs).  The pros and cons of each method are 
considered below. 
 
Compared to previous econometric models of hospital costs the WHO-CHOICE models 
exploit more extensive databases on unit costs for hospitals, health centers and salaries 
than has previously been available (Adam et al., 2003). Arguably, this wider range and 
scope of observations enhances the validity of extrapolations of cost estimates for 
countries in which data are not available. In addition the work by Adam et al. (2003) 
showed that the hospital cost regression lines had a good fit with the data used to develop 
the inpatient hospital models, implying that the models are a good predictor of country 
costs and by implication regional costs. The estimates produced by the models were also 
sent to health economists and researchers in several countries in all regions to check their 
face validity. Individuals were given a description of the estimated unit costs (including 
which costs were included) and were asked whether they thought they approximated unit 
costs found in their countries.  The findings from this consultation indicated that the 
results had good face validity (for further information see Adam et al., 2003).  
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However it is clear that there are limitations with the econometric approach adopted. First 
it assumes that GDP per capita and other macro-economic variables are able to capture 
adequately different levels of technology. The extent to which this is the case is uncertain 
and will depend on the rate of technological advances in the health sector following that 
of the economy in general. Second the approach is inevitably only as good as the studies 
included.  With respect to the hospital and health center models, many studies document 
how resources are allocated within a hospital, but these are mostly top down studies that 
do not fully take account of the different hospital cost functions which exist in facilities. 
The salaries model similarly assumes that centrally reported salary rates are reflective of 
the salary for the entire country.  In addition accounting practices vary greatly between 
countries, and this makes it more difficult (although not impossible) to generate a 
consistent set of unit costs or prices (Drummond and Pang, 2001).  Finally, it is important 
to note that WHO CHOICE are currently in the process of finalizing their data and the 
results presented here represent work in progress. For updates, interested readers are 
advised to go to the DCPP (http://www.fic.nih.gov/dcpp/index.html) and WHO CHOICE 
websites (www.who.int/evidence/cea ).  
 
The standardization approach is at first sight a more transparent method for estimating 
regional costs: estimates from one region or country are simply adjusted to reflect the 
price in another region through a regional relative price index.  The data needs for this 
approach are also much less demanding since single estimates can be transferred to other 
regions.  However, since relative price indices are an average and thus of limited 
generaliseability, this advantage is also an obvious limitation. Further, the estimation of 
the regional price is based on one or a few data points, and the quality of the results 
depend on the quality of these initial data. The method adopted here is similar to that 
employed by previous studies  (see for example Schulman et al. 1998).  The advantage of 
using an index based on hospital costs rather than a general index based on, for example, 
purchasing power parities is that it captures more accurately relative price differences in 
health care inputs rather than the economy as a whole. However, given the lack of 
regional costing work in this area (particularly that which explores the use of other types 
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of relative price indices for the health sector), it is difficult to judge to what extent our 
indices result in an over or under estimate of unit costs for these inputs in different 
regions. 
 
 
 
4.2 Conclusion 
 
 
The rapidly growing use of economic evaluation to aid decisions on the adoption and 
utilization of health technologies has generated an urgent need for comparative and 
consistent costs for key inputs. One effect of pulling together existing sources of unit 
costs is to highlight areas where further work is needed, and if cost-effectiveness analyses 
are to proceed on a multinational level, analysts must develop resource cost data that are 
comparable (Schulman et al., 1998; Drummond and Pang, 2001). It is clear from this 
work that substantial gaps remain (for example there is an urgent need for better data on 
the unit costs of diagnostic tests) and more work must be done to define consistent cost-
reporting formats for countries.  One response to this is to encourage more economic data 
collection in more countries and a wider variety of settings (Drummond et al., 1998). 
However, this paper has also argued that greater transparency in methods and sources 
will help analysts to transfer existing estimates to settings where these is little or no data 
and/or resource constraints preclude extensive data collection. This should improve the 
efficiency of economic evaluation activities overall and reduce duplication of effort. It is 
hoped that the approach described in this paper will not only provide practical means of 
transferring costs across countries and regions but also allow others to critique the 
methods adopted, thereby encouraging progress in this methodological area. 
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Annex 1.  Countries in cost analysis by regional classification 
 
Region Countries 
East Asia and 
Pacific (EAP) 
American Samoa, Cambodia, China, Fiji, Indonesia, Kiribati, Korea, Dem. Rep., 
Korea, Rep., Lao PDR, Malaysia, Marshall Islands, Micronesia, Fed. Sts., Mongolia, 
Myanmar, Palau, Papua New Guinea, Philippines, Samoa, Solomon Islands, 
Thailand, Tonga, Vanuatu, Vietnam,  
Eastern Europe 
and Central 
Asia  (EEC) 
Albania, Armenia, Azerbaijan, Belarus, Bosnia and Herzegovina, Bulgaria, Croatia, 
Czech Republic, Estonia, Georgia, Hungary, Isle of Man, Kazakhstan, Kyrgyz 
Republic, Latvia, Lithuania, Macedonia, FYR, Moldova, Poland, Romania, Russian 
Federation, Slovak Republic, Tajikistan, Turkey, Turkmenistan, Ukraine, Uzbekistan, 
Yugoslavia, Fed. Rep., 
Latin and 
Central America 
(LAC) 
Antigua and Barbuda, Argentina, Belize, Bolivia, Brazil, Chile, Colombia, Costa 
Rica, Cuba, Dominica, Dominican Republic, Ecuador, El Salvador, Grenada, 
Guatemala, Guyana, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, 
Paraguay, Peru, Puerto Rico, St. Kitts and Nevis, St. Lucia, St. Vincent and the 
Grenadines, Suriname, Trinidad and Tobago, Uruguay, Venezuela, RB, 
Middle East and 
North Africa 
(MNA) 
Algeria, Bahrain, Djibouti, Egypt, Arab Rep., Iran, Islamic Rep., Iraq, Jordan, 
Lebanon, Libya, Morocco, Oman, Saudi Arabia, Syrian Arab Republic, Tunisia, 
West Bank and Gaza, Yemen, Rep., 
South Asia (SA) Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan, Sri Lanka, 
Sub-Saharan 
Africa (SSA) 
Angola, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Central African 
Republic, Cape Verde, Chad, Comoros, Congo, Cote d’Ivoire, Dem. Republic of the 
Congo, Djibouti, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Gambia, Ghana, 
Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Madagascar, Malawi, Mali, 
Mauritania, Mozambique, Namibia, Niger, Nigeria, Rwanda, Senegal, Sierra Leone, 
Somalia, South Africa, Sudan, Swaziland, Syrian Arab Republic, Togo, Uganda, 
United Rep. Of Tanzania, Yemen, Zambia, Zimbabwe.  
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Annex 2. WHO-CHOICE models to estimate country-specific unit costs 
 
A2.1 Hospital cost per inpatient inpatient day  
 
Dependent variable: Natural log of cost per bed-day in 1998 $  
Adjusted R2= 0.80   F statistic = 509  p of F statistic <0.00001           N: 1171 
 
Variable Description β Coef SE P 
Ln GDP per capita Natural log of GDP per capita   0.7624 0.0295 <0.0001 
Ln occupancy rate Natural log of occupancy rate -0.2318 0.0474 <0.0001 
Drug costs  Dummy variable for inclusion of drug costs. 
Included =1 
 0.6410 0.1769 <0.0001 
Food costs Dummy variable for inclusion of food costs. 
Included =1 
 0.2116 0.1394    0.152 
Level 1 hospital Dummy variable for level 1 hospital -0.5777 0.0742 <0.0001 
Level 2 hospital Dummy variable for level 2 hospital  0.3118 0.0594 <0.0001 
Public Dummy variable for level public hospitals -0.2722 0.1172    0.021 
Private for profit Dummy variable for level private for profit 
hospitals 
 0.2444 0.1316    0.064 
USA Dummy variable for USA. USA  =1   1.7471 0.1022    <0.0001 
Constant  -2.5036 0.3264    0.026 
 
Smear adjustment = 1.25 
Dummy variables for levels of hospital are compared with level 3 hospitals 
Dummy variables for hospital ownership are compared with public not-for-profit hospitals  
Source: Adam et al. (2003) 
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A2.2 Hospital cost per outpatient visit  
 
The hospital cost per outpatient visit is estimated from the ratio of cost per outpatient 
visit to cost per bed day, estimated from the model presented in A2.2, and the cost per 
bed day estimated from A2.1) 
 
Dependent variable: Natural log ratio of cost per outpatient visit to cost per bed-day  
Adjusted R2= 0.63             F statistic = 85       p of F statistic <0.00001          N: 832 
 
Variable Description β Coef SE P 
Ln GDP per 
capita 
Natural log of GDP per capita in 
1998 $ 
0.11 0.03   0.003 
Ln occupancy rate Natural log of occupancy rate  0.17 0.06   0.007 
Ln hospital beds Natural log of hospital beds  0.08 0.02 <0.0001 
Public Dummy variable for level public 
hospitals (1) 
-1.63 0.63   0.009 
Ancillary costs Dummy variable for inclusion of 
ancillary (2) costs. Included =1 
-0.09 0.12   0.471 
Food costs Dummy variable for inclusion of 
food costs. Included =1 
-0.19 0.08   0.014 
Costs or charge Whether observation is cost or 
charge data. Costs =1 
 1.27 0.65   0.048 
Sri Lanka Dummy variable for Sri Lanka. Sri 
Lanka=1 
-1.21 0.10 <0.0001 
Thailand Dummy variable for Thailand. 
Thailand=1 
-0.26 0.09   0.005 
China Dummy variable for China. China=1  0.38 0.06 <0.0001 
Ecuador Dummy variable for Ecuador. 
Ecuador=1 
-0.81 0.11 <0.0001 
Constant  -2.16 0.31 <0.0001 
Smear adjustment = 1.13 
Dummy variables for hospital ownership is compared with public not-for-profit hospitals 
Ancillary costs include laboratory and other diagnostic tests. 
Source: Adam et al., Rules of Thumb for Allocating Hospital Costs Across Departments. A Multi-Country 
Analysis (forthcoming).  
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A2.3 Health center costs 
 
Dependent variable: Cost per health center visit  
Adjusted R2= 0.40                   F statistic = 82       p of F statistic <0.00001          N: 481 
  
Variable Description β Coef SE P 
Ln GDP per capita Natural log of GDP per capita  0.2926 0.0588 0.001 
Cap_incl Dummy variable for including capital costs. 
Included = 1 
0.6144 0.2423 0.043 
Anc_incl  Dummy variable for inclusion of ancillary 
services (eg lab tests). Included =1 
0.3916 0.1802 0.035 
Lnopvcap Natural log of outpatient capacity (set at 75 
visits per health worker per day) 
-0.6313 0.1149 0.001 
High Dummy variable for high income countries 
(WB regions). Included = 1 
0.9730 0.4339 0.029 
Constant  0.2008 0.5967 0.741 
     
Smear adjustment = 1.49 
Source: Adam et al., Cost of Scaling up Health Interventions at Primary Facilities. A Multi-Country 
Analysis (forthcoming). 
 
A2.4 Salaries  
 
Dependent variable: Annual salaries 
 
F statistic = 520       p of F statistic <0.00001          N: 752 
 
Variable Description β Coef SE P 
LnGDPusd Log of GDP in US dollars  0.6508 0.0135 <0.0001 
Lnpopdens Log of population density -0.0368 0.0130 0.005 
Lv1 Dummy for level 1 jobs. Included =1 -1.5921 0.1003 <0.0001 
Lv2 Dummy for level 2 jobs. Included =1 -1.3441 0.0948 <0.0001 
Lv3 Dummy for level 3 jobs. Included =1 -0.9778 0.0960 <0.0001 
Lv4 Dummy for level 4 jobs. Included =1 -0.4570 0.0994 <0.0001 
Asia Dummy if country is located in WHO regions: 
SEAR B, SEAR  D or WPRO B 
2.679 0.3461 <0.0001 
_IAsiaGDP Interaction Dummy if country located in 
SEAR B, SEAR D or WPRO B x log of GDP 
-0.4911 0.0519 <0.0001 
_ItLtnAmrGDP Dummy if country is located in AMR B, 
AMR D x log of GDP 
-0.0902 0.0075 <0.0001 
EastEur Dummy of country is located EUR B or EUR 
C 
-2.8795 0.3250 <0.0001 
_IEastEurGDP Dummy if country is located in EUR B or 
EUR C x log of GDP 
0.2552 0.0416 <0.0001 
Constant  4.9784 0.1590 <0.0001 
     
Smear adjustments by region: AFRO = 1.142; AMR B & AMR D = 1.378; EMR = 1.082, EUR B & C = 
1.269, SEAR B, SEAR D & WPR B = 1.056; AMR A, EUR A & WPR B = 1.055 
Dummy variables for job levels compared to level 5 jobs 
Source:  Johns et al., Determinants of Variation in Health Sector Wages Across Countries (forthcoming). 
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